OncoMatch/Clinical Trials/NCT06259123
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Is NCT06259123 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [177Lu]Lu-PSMA I&T for prostate cancer.
Treatment: [177Lu]Lu-PSMA I&T — Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy \[177Lu\]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical prostatectomy (RP) for oligometastatic prostate cancer (PCa) diagnosed using \[68Ga\]Ga-PSMA-11 PET examination. Ten patients with oligometastatic primary PCa diagnosed using \[68Ga\]Ga-PSMA-11 PET-CT/MRI imaging will be included in this study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: androgen deprivation therapy
Ongoing or previous androgen deprivation therapy with agonist or antagonist therapies
Lab requirements
Blood counts
WBC ≥1.5 x 10^9 /L, Platelets ≥100 x 10^9 /L and Haemoglobin ≥9 g/dL
Kidney function
eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL
Patients must have adequate bone marrow reserve: WBC ≥1.5 x 10^9 /L, Platelets ≥100 x 10^9 /L and Haemoglobin ≥9 g/dL. Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify